Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
Clinical trial NCT04901741 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT04901741
- Sponsor
- TME Pharma AG
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-01
- Primary completion
- 2028-03-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.